Purpose: To evaluate the clinical characteristics and surgical outcome of macular tractional retinoschisis (TRS) as compared with tractional retinal detachment (TRD) in proliferative diabetic retinopathy (PDR). Methods: This retrospective, longitudinal study collected consecutive cases with optical coherence tomography (OCT)-confirmed TRS and TRD between January 2007 and June 2013. All cases had surgical treatment. Their preoperative findings and follow-up data were subsequently compared. Results: Thirty-two eyes (32 patients) with TRS and 32 eyes (32 patients) with TRD were included. The TRS group had more clinically inactive fibrosis and less extensive fibrovascular proliferation than the TRD group. The involved area and height of the schisis varied among cases; associated macular abnormalities included inner macular cyst (43.75%), lamellar hole (12.5%) and foveal detachment (9.38%); sequential OCT in some cases showed a progression of macular changes. Both groups had significant visual improvement after surgery. Of the patients with TRS, 40.62% had residual retinoschisis. Preoperative best-corrected visual acuity (BCVA), postoperative BCVA and improvement in visual acuity showed no significant difference between TRS and TRD. Conclusions: Unique features exist for macular TRS in PDR. Visual function may benefit from vitreous surgery despite residual macular abnormalities in some cases.

Keywords:
Macular retinoschisis, Traction, Diabetes
1.
Imai M, Iijima H, Hanada N: Optical coherence tomography of tractional macular elevations in eyes with proliferative diabetic retinopathy. Am J Ophthalmol 2001;132:458-461.
2.
Gupta B, Sivaprasad S, Wong R, Laidlaw A, Jackson TL, McHugh D, Williamson TH: Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK study. Eye (Lond) 2012;26:510-516.
3.
da R Lucena D, Ribeiro JA, Costa RA, Barbosa JC, Scott IU, de Figueiredo-Pontes LL, Jorge R: Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009;93:688-691.
4.
Faulborn J, Ardjomand N: Tractional retinoschisis in proliferative diabetic retinopathy: a histopathological study. Graefes Arch Clin Exp Ophthalmol 2000;238:40-44.
5.
Lincoff H, Serag Y, Chang S, Silverman R, Bondok B, el-Aswad M: Tractional elevations of the retina in patients with diabetes. Am J Ophthalmol 1992;113:235-242.
6.
Iijima H, Imai M: Differentiation of retinal detachment from retinoschisis using optical coherence tomography. Am J Ophthalmol 2003;136:577, author reply 577-578.
7.
Kay CN, Gendy MG, Lujan BJ, Punjabi OS, Gregori G, Flynn HW Jr: Composite spectral domain optical coherence tomography images of diabetic tractional retinal detachment. Ophthalmic Surg Lasers Imaging 2008;39(4 suppl):S99-S103.
8.
Shih CW, Yang CM, Chen MS, Wang TJ: Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation. Graefes Arch Clin Exp Ophthalmol 2008;246:1547-1551.
9.
Yeh PT, Yang CM, Huang JS, Chien CT, Yang CH, Chiang YH, Shih YF: Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology 2008;115:734e1-737e1.
10.
Chapter 1: Basic anatomy; in Regillo CD (ed): Basic and Clinical Science Course 2010-2011. Section 12: Retina and Vitreous. San Francisco, American Academy of Ophthalmology, 2010, pp 8-10.
11.
Yang CM, Yeh PT, Yang CH: Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007;114:710-715.
12.
Cheema RA, Mushtaq J, Al-Khars W, Al-Askar E, Cheema MA: Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage. Retina 2010;30:1646-1650.
13.
Tibbetts MD, Shah CP, Young LH, Duker JS, Maguire JI, Morley MG: Treatment of acute retinal necrosis. Ophthalmology 2010;117:818-824.
14.
Abu El-Asrar AM, Nawaz MI, Kangave D, Siddiquei MM, Ola MS, Opdenakker G: Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy. Acta Diabetol 2011, E-pub ahead of print.
15.
Yang CM, Yeh PT, Yang CH, Chen MS: Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008;146:211-217.
16.
Nicholson BP, Schachat AP: A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-930.
17.
Waisbourd M, Goldstein M, Loewenstein A: Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol 2011;89:203-207.
18.
Wakabayashi T, Fujiwara M, Sakaguchi H, Kusaka S, Oshima Y: Foveal microstructure and visual acuity in surgically closed macular holes: spectral-domain optical coherence tomographic analysis. Ophthalmology 2010;117:1815-1824.
19.
Ko TH, Witkin AJ, Fujimoto JG, Chan A, Rogers AH, Baumal CR, Schuman JS, Drexler W, Reichel E, Duker JS: Ultrahigh-resolution optical coherence tomography of surgically closed macular holes. Arch Ophthalmol 2006;124:827-836.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.